Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$915.04 USD

915.04
2,445,728

+10.07 (1.11%)

Updated Sep 19, 2024 04:00 PM ET

After-Market: $911.40 -3.64 (-0.40%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?

by Kinjel Shah

SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.

Kinjel Shah headshot

Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

by Kinjel Shah

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

by Zacks Equity Research

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

Sweta Killa headshot

Tap the Weight-Loss Drug Market With These ETFs

by Sweta Killa

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

by Zacks Equity Research

The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

Kinjel Shah headshot

Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?

by Kinjel Shah

Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.

Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

by Zacks Equity Research

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

Is Most-Watched Stock Eli Lilly and Company (LLY) Worth Betting on Now?

by Zacks Equity Research

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Lilly Gets FDA Approval for Eczema Drug Ebglyss

by Zacks Equity Research

The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.

Panel Of Zacks Experts headshot

Top Stock Picks for Week of September 16, 2024

by Panel Of Zacks Experts

One of the Largest Pharmaceutical Companies and an Emerging Growth Company are Profiled.

Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

by Zacks Equity Research

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.

Kinjel Shah headshot

NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise

by Kinjel Shah

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

by Zacks Equity Research

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

by Zacks Equity Research

With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.

Ahan Chakraborty headshot

Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

by Ahan Chakraborty

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

by Zacks Equity Research

RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.

Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day.

Ethan Feller headshot

Bull of the Day: Eli Lilly (LLY)

by Ethan Feller

Eli Lilly stock boasts both defensive and growth characteristics

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Mark Vickery headshot

Top Stock Reports for Visa, AbbVie & Anheuser-Busch

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).

Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug

by Zacks Equity Research

TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.

Best Momentum Stocks to Buy for September 10th

by Zacks Equity Research

LLY, MCO, and BCH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 10, 2024.

MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study

by Zacks Equity Research

Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.

Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg

by Zacks Equity Research

BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.

New Strong Buy Stocks for September 10th

by Zacks Equity Research

CLCO, BCH, ZUO, LLY and LYTS have been added to the Zacks Rank #1 (Strong Buy) List on September 10, 2024.